23andMe files for bankruptcy: what went wrong?
23andMe, the genetics testing company once valued at $6 billion, has filed for Chapter 11 bankruptcy protection in the US....
23andMe, the genetics testing company once valued at $6 billion, has filed for Chapter 11 bankruptcy protection in the US....
Investors have closely watched Nvidia’s week-long GPU Technology Conference (GTC) for news and updates from the dominant maker of chips that...
The blue-chip Dow Jones index has crashed this year as concerns about Donald Trump’s tariffs and the bursting of the...
The USD/JPY exchange rate was in the spotlight last week as the Federal Reserve delivered its March interest rate decision...
Coinbase stock price has crashed into a bear market this year as the crypto industry remains on edge, with most...
As top U.S. officials prepare for a meeting with a Russian delegation in Saudia Arabia Sunday, questions have mounted over...
Dozens of Tesla vehicles were damaged at a dealership in Ontario, Canada, Hamilton Police Service (HPS) confirmed to Fox News...
President Donald Trump revoked the security clearances of Joe Biden, Hillary Clinton, Kamala Harris, Liz Cheney and several other opponents...
FIRST ON FOX: President Donald Trump’s administration’s use of Elon Musk’s DOGE to cut USAID spending is having a deep...
A top former Bush administration lawyer is warning the White House not to begin ignoring court orders amid its standoff...
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.